Eli Lilly And Company ((LLY)), Cipla Ltd ((IN:CIPLA)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: Eli Lilly and Company, in collaboration with Cipla Ltd., is conducting a Phase 4 clinical study titled A 26-Week, Multicenter, Open-Label, Single-Arm, Phase 4 Study to Assess The Safety of Lyumjev in Adult Patients With Type 2 Diabetes Mellitus in India. The study aims to evaluate the safety of insulin lispro-aabc in adult participants with Type 2 diabetes mellitus in India, highlighting its significance for diabetes management in the region.
Intervention/Treatment: The study tests the combination of insulin lispro-aabc and insulin glargine, both administered via subcutaneous injection. These drugs are intended to manage blood sugar levels in patients with Type 2 diabetes.
Study Design: This interventional study follows a single-group model without masking, focusing on treatment as its primary purpose. Participants receive the experimental combination of insulin lispro-aabc and insulin glargine.
Study Timeline: The study began on April 18, 2024, with an active, not recruiting status as of the last update on July 22, 2025. The study spans approximately 33 weeks per participant, including screening, lead-in, treatment, and follow-up periods.
Market Implications: The study’s progress could influence Eli Lilly’s and Cipla’s stock performance, as successful results may bolster investor confidence and enhance their market position in diabetes treatment. The outcome could also impact competitive dynamics in the pharmaceutical industry, particularly in the diabetes segment.
The study is ongoing, with further details available on the ClinicalTrials portal.